Yukon and Northwest Territories have accepted Prime Minister Justin Trudeau's health funding proposal, securing $380 million and $361 million respectively over 10 years. The agreements include increased health-care transfers and $73 million dedicated to each territory's specific concerns. Trudeau's offer was made in response to concerns about a national health-care crisis.
Tick samples from Prince Edward Island (P.E.I.) now have a 1 in 5 chance of testing positive for Lyme disease, up from the usual 1 in 10, according to a New Brunswick laboratory. The increase may be due to mild winters in P.E.I. that favor tick survival. Lyme cases are rising across Canada, with provinces like Nova Scotia and Ontario being particularly affected. Public health offices are advised to monitor tick-related data as ticks carry various diseases, some more severe than Lyme disease.
This alternative procedure involves inserting a catheter through the patient's neck or groin, reducing risks and recovery time. The new method allows doctors to diagnose heart conditions more efficiently and may lead to improved patient outcomes.
COVID-19 claims 16 more lives in New Brunswick, bringing the death toll to 913. The latest update reveals that all cases in the province are now linked to the Omicron variant XBB. The COVIDWatch report discloses that one victim was under 50, while the remaining 15 were aged 70 or above. Detailed information on the deaths, including dates, is yet to be obtained from the Department of Health, as CBC has requested.
Yellowknife health services are experiencing reductions and longer wait times due to staffing challenges, according to the Northwest Territories Health and Social Services Authority. The lab collection site at Yellowknife Primary Care Clinic will be closed for two weeks, while the lab at Stanton Territorial Hospital will remain open. Patients may struggle to book preferred appointments and expect longer waits for primary care. Recruitment challenges are expected to persist throughout the summer.
Canadians are experiencing an overwhelming amount of marketing for the diabetes medications Ozempic and Rybelsus. Ads for these drugs can be found on different platforms, and even at professional sports games. Both Ozempic and Rybelsus, manufactured by Novo Nordisk, are semaglutide drugs approved for treating Type 2 diabetes. Doctors and experts fear that the extensive ads may pressure unnecessary prescriptions.
We'll keep you updated on all new application updates and features!